PSG Validation Study of Zensorium Biosensing Wearable Device

Completed

• Conditions: Healthy; Sleep Wake Disorders

• Registration Number: NCT04200495
• Lead Sponsor: University of California, San Diego

Brief Summary

The objective of this study is to collect data comparing the Zensorium Biosensing Wearable Device (zBWD) to polysomnography (PSG) in individuals with Sleep-Wake Disorders. zBWD is similar to other wearable devices (e.g., fitbit and apple watch) that use an optical light sensor and Tri-axis Accelerometer to record steps, activity, sleep/awake states, sleep staging, and statistical variation of pulse pressure to track stress. Specifically, it is designed to report sleep duration, non-rapid eye movement (NREM) and REM sleep duration. However, zBWD has not been validated against PSG for sleep tracking in healthy controls or in individuals with sleep-wake disorders.

Detailed Description

Subjects known to have or not have sleep-wake disorder, as well as healthy subjects, will be enrolled if they otherwise meet all the inclusion criteria, and none of the exclusion criteria. Subject will be asked to complete several questionnaires and wear the zBWD for 7-days, in an off-site (Home) study, followed by a single overnight PSG study to compare the zBWD data to the current gold standard of PSG. Subjects who have completed the study will also be sent a letter thanking them for their participation and offering a summary of the results of their sleep study.

Study Timeline

• Study Start: 2019-11-20
• Study First Submitted: 2019-12-06
• Study First Submitted QC: 2019-12-13
• Study First Posted: 2019-12-16
• Primary Completion: 2020-10-28
• Study Completion: 2020-10-28
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

• 1. Health status: Healthy, or those with sleep-wake disorders

Exclusion Criteria

1. Pregnancy
2. Currently smoking
3. Any respiratory disorder other than associated with Sleep/Wake Disorder or well-controlled asthma
4. Habitual use of medications known to affect respiratory function (e.g. opioids, benzodiazepines, etc).
5. Use of medication known to affect pulse pressure (Beta Blockers)
6. Atrial Fibrillation
7. Tattoos located on wrist

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
polysomnography derived percent REM and percent non-REM sleep	One overnight stay at Visit 2 (7 - 10 days following Baseline)	A full clinical overnight polysomnography (PSG) study will be performed 7 - 10 days following visit 1. The subject will have EEG, EMG, EOG, and ECG electrodes, an adhesive body position sensor placed in standard locations. This equipment is standard for diagnostic PSG. The variables of interest from the PSG are stages of sleep as indicated by PSG including % rapid eye movement (REM; amount of time in REM sleep/Total sleep time) and % non-REM (amount of time in non-REM sleep/Total sleep time)
Zensorium derived percent REM and percent Non-REM sleep	To be worn everyday between Baseline to visit 2 (7 -10 days)	Zensorium Biosensing Wearable Device (zBWD) will be worn for 7 to 10 days following visit 1. The variables of interest are stages of sleep as indicated by the zBWD including % rapid eye movement (REM; amount of time in REM sleep/Total sleep time) and % non-REM (amount of time in non-REM sleep/Total sleep time).

Secondary Outcome Measures

Name	Time	Method
Sleep Diary	To be filled out everyday between Baseline to visit 2 (7 -10 days)	Tracking off-site (home) sleep for 7 to 10 days via self report diary - Sleep Efficiency, Total Sleep Time, Sleep latency, and Wake after sleep onset
Pre-Sleep Arousal Scale	Baseline	Pre-sleep arousal scale (PSAS) is a self-administered measure in which participants rate the intensity of experienced arousal for somatic (8 items) and cognitive (8 items) subscales. The PSAS shows strong internal consistency and reliability. Higher scores indicate worse pre-sleep arousal. Ratings range from 1 (not at all) to 5 (extremely).
Insomnia Severity Index	Baseline	Insomnia Severity Index (ISI) is a widely used measure of insomnia with well-established reliability and validity. The ISI consists of seven items, three of which assess severity of insomnia (i.e., degree of difficulty falling asleep, staying asleep, and waking too early). The remaining questions tap satisfaction with sleep pattern, effect of sleep on daytime and social functioning, and concern about current sleep difficulties. Ranges from 0 (no insomnia) to 28 (Severe insomnia)
Epworth Sleepiness Scale	Baseline	Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The questions measure participants experiences of having dozed off or fallen asleep while engaged in eight different activities that differ widely in their somnificity (including sitting in traffic or watching television). can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'
Berlin Questionnaire	Baseline	Berlin Questionnaire is a validated screening tool for sleep disordered breather. One question and four follow-up questions concern snoring; three questions address daytime sleepiness, with a subquestion about sleepiness behind the wheel. Lastly, the measure addresses history of high blood pressure, age, weight, height, sex, neck circumference, and ethnicity. High Risk is considered if there are 2 or more categories where the score is positive, where more categories endorsed equates to higher risk.

Trial Locations

Locations (1)

University of California San Diego; 🇺🇸 San Diego, California, United States